 Richard Vandivier
Concepts (441)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Disease, Chronic Obstructive | 21 | 2025 | 1040 | 3.190 |
Why?
| | Apoptosis | 23 | 2014 | 2553 | 2.120 |
Why?
| | Phagocytosis | 15 | 2014 | 380 | 1.960 |
Why?
| | Macrophages, Alveolar | 14 | 2019 | 391 | 1.200 |
Why?
| | Tobacco Smoke Pollution | 3 | 2022 | 261 | 1.130 |
Why?
| | Tissue Plasminogen Activator | 2 | 2018 | 224 | 1.050 |
Why?
| | Pulmonary Embolism | 2 | 2018 | 226 | 0.990 |
Why?
| | Respiratory Insufficiency | 4 | 2024 | 318 | 0.900 |
Why?
| | Lung | 13 | 2025 | 4060 | 0.730 |
Why?
| | Smoking | 5 | 2018 | 1627 | 0.700 |
Why?
| | Cigarette Smoking | 2 | 2025 | 101 | 0.690 |
Why?
| | Adrenal Cortex Hormones | 2 | 2015 | 565 | 0.680 |
Why?
| | rhoA GTP-Binding Protein | 6 | 2014 | 86 | 0.650 |
Why?
| | Pulmonary Ventilation | 2 | 2018 | 79 | 0.620 |
Why?
| | Extracorporeal Membrane Oxygenation | 1 | 2022 | 301 | 0.600 |
Why?
| | Pneumonia | 6 | 2023 | 639 | 0.550 |
Why?
| | Delivery of Health Care, Integrated | 2 | 2011 | 261 | 0.540 |
Why?
| | Fibrinolytic Agents | 1 | 2018 | 270 | 0.490 |
Why?
| | rac1 GTP-Binding Protein | 3 | 2012 | 56 | 0.450 |
Why?
| | Pulmonary Alveoli | 4 | 2016 | 405 | 0.450 |
Why?
| | Stem Cells | 2 | 2018 | 594 | 0.440 |
Why?
| | Methylprednisolone | 1 | 2014 | 86 | 0.430 |
Why?
| | Critical Illness | 8 | 2020 | 811 | 0.420 |
Why?
| | Serotonin Plasma Membrane Transport Proteins | 1 | 2014 | 75 | 0.420 |
Why?
| | Pulmonary Surfactant-Associated Protein D | 5 | 2016 | 35 | 0.410 |
Why?
| | Hospital Mortality | 6 | 2025 | 911 | 0.410 |
Why?
| | Bronchiectasis | 2 | 2006 | 111 | 0.400 |
Why?
| | Intensive Care Units | 6 | 2025 | 827 | 0.400 |
Why?
| | Hypnotics and Sedatives | 2 | 2025 | 200 | 0.390 |
Why?
| | Alcoholism | 5 | 2023 | 807 | 0.390 |
Why?
| | Case Management | 1 | 2012 | 66 | 0.380 |
Why?
| | Humans | 67 | 2025 | 137585 | 0.380 |
Why?
| | Coronary Disease | 1 | 2015 | 385 | 0.380 |
Why?
| | Vascular Endothelial Growth Factor A | 3 | 2016 | 545 | 0.380 |
Why?
| | Asthma | 3 | 2022 | 2295 | 0.380 |
Why?
| | rho GTP-Binding Proteins | 2 | 2010 | 60 | 0.370 |
Why?
| | Noninvasive Ventilation | 2 | 2024 | 51 | 0.360 |
Why?
| | Serotonin | 1 | 2014 | 323 | 0.360 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 1 | 2012 | 71 | 0.360 |
Why?
| | Cystic Fibrosis | 4 | 2006 | 1114 | 0.340 |
Why?
| | Pulmonary Surfactant-Associated Protein A | 3 | 2008 | 35 | 0.330 |
Why?
| | Patient Education as Topic | 2 | 2012 | 766 | 0.330 |
Why?
| | Inflammation Mediators | 4 | 2016 | 513 | 0.310 |
Why?
| | Neutrophils | 7 | 2010 | 1238 | 0.300 |
Why?
| | Mice | 21 | 2017 | 17787 | 0.300 |
Why?
| | Male | 38 | 2025 | 67762 | 0.300 |
Why?
| | Jurkat Cells | 6 | 2012 | 134 | 0.290 |
Why?
| | Interleukin-8 | 1 | 2009 | 268 | 0.290 |
Why?
| | Female | 36 | 2025 | 73304 | 0.280 |
Why?
| | Low Density Lipoprotein Receptor-Related Protein-1 | 3 | 2006 | 18 | 0.280 |
Why?
| | Dose-Response Relationship, Drug | 5 | 2018 | 2057 | 0.280 |
Why?
| | Hospitalization | 5 | 2023 | 2199 | 0.270 |
Why?
| | Signal Transduction | 6 | 2014 | 5079 | 0.270 |
Why?
| | Cells, Cultured | 9 | 2016 | 4193 | 0.270 |
Why?
| | Animals | 30 | 2017 | 36940 | 0.270 |
Why?
| | Benzodiazepines | 2 | 2025 | 155 | 0.270 |
Why?
| | Middle Aged | 23 | 2025 | 33479 | 0.270 |
Why?
| | Acyl Coenzyme A | 1 | 2006 | 31 | 0.260 |
Why?
| | Intracellular Fluid | 1 | 2006 | 27 | 0.260 |
Why?
| | rho-Associated Kinases | 3 | 2014 | 83 | 0.260 |
Why?
| | Inflammation | 9 | 2016 | 2837 | 0.250 |
Why?
| | Lovastatin | 1 | 2006 | 37 | 0.250 |
Why?
| | Quality of Life | 3 | 2022 | 2892 | 0.250 |
Why?
| | Lung Diseases, Obstructive | 1 | 2006 | 50 | 0.250 |
Why?
| | Collectins | 1 | 2006 | 12 | 0.250 |
Why?
| | Opsonin Proteins | 1 | 2006 | 25 | 0.250 |
Why?
| | Self Care | 1 | 2009 | 380 | 0.240 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2009 | 329 | 0.240 |
Why?
| | Chemotaxis, Leukocyte | 1 | 2006 | 136 | 0.240 |
Why?
| | Ethanol | 1 | 2010 | 608 | 0.240 |
Why?
| | Retrospective Studies | 13 | 2025 | 15657 | 0.240 |
Why?
| | Neuromuscular Blockade | 1 | 2025 | 31 | 0.230 |
Why?
| | Leukocyte Elastase | 2 | 2002 | 76 | 0.230 |
Why?
| | Mice, Knockout | 8 | 2014 | 3015 | 0.230 |
Why?
| | Propofol | 1 | 2025 | 73 | 0.230 |
Why?
| | Mice, Inbred C57BL | 11 | 2014 | 5757 | 0.220 |
Why?
| | Influenza A virus | 1 | 2025 | 107 | 0.220 |
Why?
| | Oligopeptides | 1 | 2006 | 271 | 0.220 |
Why?
| | Cohort Studies | 6 | 2022 | 5742 | 0.210 |
Why?
| | Shock, Septic | 2 | 2022 | 219 | 0.210 |
Why?
| | Complement C1q | 2 | 2006 | 37 | 0.210 |
Why?
| | Ibuprofen | 4 | 2001 | 84 | 0.210 |
Why?
| | Disease Progression | 4 | 2020 | 2757 | 0.210 |
Why?
| | Patient Admission | 1 | 2025 | 197 | 0.210 |
Why?
| | Aged | 16 | 2025 | 23961 | 0.200 |
Why?
| | Erythropoietin | 1 | 2004 | 95 | 0.200 |
Why?
| | Respiratory System | 2 | 2018 | 157 | 0.200 |
Why?
| | Lipopolysaccharides | 5 | 2016 | 886 | 0.200 |
Why?
| | Intracellular Signaling Peptides and Proteins | 2 | 2025 | 455 | 0.200 |
Why?
| | Calreticulin | 1 | 2002 | 28 | 0.200 |
Why?
| | Extracellular Matrix | 1 | 2006 | 528 | 0.180 |
Why?
| | Adult | 21 | 2025 | 37929 | 0.180 |
Why?
| | Patient Discharge | 2 | 2018 | 897 | 0.180 |
Why?
| | Treatment Outcome | 5 | 2022 | 10811 | 0.180 |
Why?
| | Smoke-Free Policy | 1 | 2021 | 13 | 0.170 |
Why?
| | Transforming Growth Factor beta | 4 | 2013 | 480 | 0.170 |
Why?
| | Macrophages | 5 | 2010 | 1547 | 0.170 |
Why?
| | Smokers | 2 | 2019 | 145 | 0.170 |
Why?
| | Analgesics, Opioid | 2 | 2025 | 1000 | 0.160 |
Why?
| | Mice, Inbred ICR | 3 | 2013 | 119 | 0.160 |
Why?
| | Tumor Necrosis Factor-alpha | 6 | 2009 | 1242 | 0.160 |
Why?
| | Endotoxins | 5 | 2013 | 220 | 0.160 |
Why?
| | Autoimmune Diseases | 2 | 2014 | 460 | 0.160 |
Why?
| | Receptors, Cell Surface | 1 | 2002 | 385 | 0.160 |
Why?
| | Granulomatous Disease, Chronic | 2 | 2010 | 55 | 0.160 |
Why?
| | Nitroprusside | 1 | 1999 | 69 | 0.160 |
Why?
| | Speech Therapy | 1 | 2019 | 21 | 0.150 |
Why?
| | Hexosaminidases | 1 | 2019 | 18 | 0.150 |
Why?
| | Heparin, Low-Molecular-Weight | 1 | 2018 | 34 | 0.150 |
Why?
| | Influenza, Human | 1 | 2025 | 622 | 0.150 |
Why?
| | Macrolides | 1 | 2019 | 65 | 0.150 |
Why?
| | Pharmacoepidemiology | 2 | 2019 | 19 | 0.150 |
Why?
| | Vecuronium Bromide | 1 | 2018 | 6 | 0.150 |
Why?
| | Intubation, Intratracheal | 1 | 2020 | 257 | 0.140 |
Why?
| | Atracurium | 1 | 2018 | 14 | 0.140 |
Why?
| | Heart Failure, Diastolic | 1 | 2018 | 21 | 0.140 |
Why?
| | Heart Failure, Systolic | 1 | 2018 | 25 | 0.140 |
Why?
| | Neuromuscular Blocking Agents | 1 | 2018 | 26 | 0.140 |
Why?
| | Cardiologists | 1 | 2018 | 45 | 0.140 |
Why?
| | Coronary Circulation | 1 | 2018 | 143 | 0.140 |
Why?
| | Bronchoalveolar Lavage Fluid | 5 | 2016 | 652 | 0.140 |
Why?
| | Time | 1 | 2018 | 83 | 0.140 |
Why?
| | Counseling | 1 | 2021 | 391 | 0.140 |
Why?
| | Occupational Therapy | 1 | 2019 | 100 | 0.140 |
Why?
| | Polyneuropathies | 1 | 2017 | 55 | 0.140 |
Why?
| | Up-Regulation | 2 | 2019 | 843 | 0.130 |
Why?
| | Aged, 80 and over | 7 | 2022 | 7635 | 0.130 |
Why?
| | Factor Xa Inhibitors | 1 | 2018 | 172 | 0.130 |
Why?
| | Epithelium | 1 | 2018 | 313 | 0.130 |
Why?
| | Disease Models, Animal | 5 | 2017 | 4295 | 0.130 |
Why?
| | Disease-Free Survival | 1 | 2018 | 686 | 0.130 |
Why?
| | Hypertension, Pulmonary | 4 | 2016 | 1910 | 0.130 |
Why?
| | Anti-Bacterial Agents | 2 | 2019 | 1809 | 0.130 |
Why?
| | Critical Care | 2 | 2020 | 601 | 0.130 |
Why?
| | Nitric Oxide | 3 | 2006 | 915 | 0.130 |
Why?
| | Practice Patterns, Physicians' | 1 | 2025 | 1313 | 0.130 |
Why?
| | Propensity Score | 2 | 2017 | 294 | 0.130 |
Why?
| | Ventricular Function, Left | 2 | 2018 | 534 | 0.130 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2018 | 209 | 0.130 |
Why?
| | Substance-Related Disorders | 1 | 2025 | 1083 | 0.130 |
Why?
| | Receptors, IgG | 2 | 2009 | 75 | 0.120 |
Why?
| | DNA, Bacterial | 1 | 2017 | 337 | 0.120 |
Why?
| | Environmental Exposure | 1 | 2021 | 579 | 0.120 |
Why?
| | Physical Therapy Modalities | 1 | 2019 | 308 | 0.120 |
Why?
| | Antibodies, Monoclonal | 2 | 2014 | 1430 | 0.120 |
Why?
| | Length of Stay | 3 | 2019 | 1215 | 0.120 |
Why?
| | Respiratory Tract Diseases | 1 | 2017 | 184 | 0.120 |
Why?
| | Respiratory Mucosa | 2 | 2009 | 321 | 0.120 |
Why?
| | Opioid-Related Disorders | 1 | 2023 | 515 | 0.120 |
Why?
| | Emphysema | 3 | 2012 | 106 | 0.120 |
Why?
| | CD36 Antigens | 2 | 2006 | 36 | 0.110 |
Why?
| | Venous Thromboembolism | 1 | 2018 | 316 | 0.110 |
Why?
| | Biopsy | 1 | 2018 | 1129 | 0.110 |
Why?
| | Gene Expression Regulation | 4 | 2014 | 2607 | 0.110 |
Why?
| | Hyaluronan Receptors | 2 | 2006 | 102 | 0.110 |
Why?
| | Anticoagulants | 1 | 2018 | 664 | 0.110 |
Why?
| | Schistosomiasis mansoni | 1 | 2013 | 23 | 0.100 |
Why?
| | Gastrointestinal Agents | 1 | 2014 | 65 | 0.100 |
Why?
| | Schistosoma mansoni | 1 | 2013 | 37 | 0.100 |
Why?
| | Epithelial Cells | 3 | 2025 | 1096 | 0.100 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2016 | 238 | 0.100 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2014 | 346 | 0.100 |
Why?
| | Leukocytes, Mononuclear | 1 | 2016 | 558 | 0.100 |
Why?
| | Respiration, Artificial | 3 | 2025 | 645 | 0.100 |
Why?
| | Echocardiography | 1 | 2016 | 642 | 0.100 |
Why?
| | Thymus Gland | 1 | 2014 | 312 | 0.100 |
Why?
| | Biological Transport | 1 | 2014 | 418 | 0.100 |
Why?
| | Patient Acceptance of Health Care | 1 | 2019 | 806 | 0.100 |
Why?
| | Interleukin-6 | 3 | 2013 | 778 | 0.100 |
Why?
| | Mice, Transgenic | 3 | 2013 | 2167 | 0.090 |
Why?
| | Cell Line | 4 | 2012 | 2847 | 0.090 |
Why?
| | Acute Disease | 1 | 2015 | 1007 | 0.090 |
Why?
| | Doxycycline | 1 | 2012 | 62 | 0.090 |
Why?
| | Phosphatidylserines | 2 | 2008 | 91 | 0.090 |
Why?
| | United States | 7 | 2025 | 14841 | 0.090 |
Why?
| | Acetylcysteine | 2 | 2016 | 145 | 0.090 |
Why?
| | Colitis | 1 | 2014 | 266 | 0.090 |
Why?
| | Pyrroles | 1 | 2012 | 213 | 0.090 |
Why?
| | Bronchoalveolar Lavage | 3 | 2017 | 93 | 0.090 |
Why?
| | Erythrocytes | 2 | 2009 | 700 | 0.090 |
Why?
| | Rural Health Services | 1 | 2011 | 128 | 0.080 |
Why?
| | Glucocorticoids | 1 | 2015 | 594 | 0.080 |
Why?
| | Adolescent | 5 | 2022 | 21513 | 0.080 |
Why?
| | Anti-Inflammatory Agents | 1 | 2014 | 496 | 0.080 |
Why?
| | Multivariate Analysis | 1 | 2014 | 1509 | 0.080 |
Why?
| | Membrane Glycoproteins | 3 | 2010 | 500 | 0.080 |
Why?
| | In Vitro Techniques | 2 | 2002 | 1092 | 0.080 |
Why?
| | Acute Lung Injury | 1 | 2013 | 287 | 0.080 |
Why?
| | Severity of Illness Index | 1 | 2018 | 2828 | 0.080 |
Why?
| | Amides | 1 | 2010 | 93 | 0.080 |
Why?
| | Peritonitis | 1 | 2010 | 84 | 0.080 |
Why?
| | Ceramides | 1 | 2010 | 118 | 0.080 |
Why?
| | Membrane Proteins | 3 | 2006 | 1164 | 0.080 |
Why?
| | Sepsis | 3 | 2020 | 617 | 0.080 |
Why?
| | Health Care Surveys | 1 | 2011 | 565 | 0.080 |
Why?
| | Stress Fibers | 1 | 2009 | 19 | 0.080 |
Why?
| | Amiloride | 1 | 2009 | 26 | 0.080 |
Why?
| | Thiazolidinediones | 1 | 2010 | 137 | 0.080 |
Why?
| | Endotoxemia | 2 | 2001 | 86 | 0.080 |
Why?
| | Microbiota | 1 | 2017 | 762 | 0.080 |
Why?
| | Phosphorylation | 1 | 2014 | 1759 | 0.080 |
Why?
| | Alcohol-Related Disorders | 1 | 2010 | 122 | 0.080 |
Why?
| | PPAR gamma | 1 | 2010 | 182 | 0.080 |
Why?
| | Indoles | 1 | 2012 | 412 | 0.070 |
Why?
| | Oxygen Consumption | 1 | 2011 | 696 | 0.070 |
Why?
| | Drug Administration Schedule | 1 | 2010 | 786 | 0.070 |
Why?
| | Antigens, Differentiation | 1 | 2008 | 83 | 0.070 |
Why?
| | Telephone | 1 | 2009 | 173 | 0.070 |
Why?
| | Statistics, Nonparametric | 1 | 2009 | 431 | 0.070 |
Why?
| | Interleukin-4 | 1 | 2008 | 216 | 0.070 |
Why?
| | Risk Factors | 4 | 2018 | 10388 | 0.070 |
Why?
| | Gene Expression | 2 | 2010 | 1502 | 0.070 |
Why?
| | Actins | 1 | 2009 | 416 | 0.070 |
Why?
| | Receptors, Immunologic | 1 | 2008 | 216 | 0.070 |
Why?
| | Blotting, Western | 1 | 2009 | 1226 | 0.060 |
Why?
| | Cross-Sectional Studies | 1 | 2018 | 5472 | 0.060 |
Why?
| | Free Radical Scavengers | 1 | 2006 | 88 | 0.060 |
Why?
| | Hydroxymethylglutaryl CoA Reductases | 1 | 2006 | 14 | 0.060 |
Why?
| | Pyridines | 1 | 2010 | 506 | 0.060 |
Why?
| | Protein Prenylation | 1 | 2006 | 34 | 0.060 |
Why?
| | Models, Biological | 1 | 2014 | 1783 | 0.060 |
Why?
| | Heart Rate | 3 | 2005 | 822 | 0.060 |
Why?
| | Mannose-Binding Lectin | 1 | 2006 | 23 | 0.060 |
Why?
| | Down-Regulation | 2 | 2025 | 657 | 0.060 |
Why?
| | Lysophospholipids | 1 | 2006 | 80 | 0.060 |
Why?
| | Protein Biosynthesis | 1 | 2008 | 433 | 0.060 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2006 | 171 | 0.060 |
Why?
| | ATP-Binding Cassette Transporters | 1 | 2006 | 137 | 0.060 |
Why?
| | Transcription, Genetic | 2 | 2010 | 1457 | 0.060 |
Why?
| | Parenteral Nutrition | 1 | 2006 | 107 | 0.060 |
Why?
| | Receptors, Complement | 1 | 2006 | 122 | 0.060 |
Why?
| | Health Care Costs | 1 | 2009 | 398 | 0.060 |
Why?
| | omega-N-Methylarginine | 1 | 2005 | 27 | 0.060 |
Why?
| | Arginine | 1 | 2006 | 271 | 0.060 |
Why?
| | Bronchi | 1 | 2006 | 260 | 0.060 |
Why?
| | Enhancer of Zeste Homolog 2 Protein | 1 | 2025 | 51 | 0.060 |
Why?
| | Antigens, CD | 2 | 2006 | 521 | 0.060 |
Why?
| | Regeneration | 1 | 2006 | 197 | 0.060 |
Why?
| | Patient Satisfaction | 1 | 2009 | 660 | 0.060 |
Why?
| | Single-Blind Method | 3 | 2001 | 282 | 0.060 |
Why?
| | MAP Kinase Signaling System | 1 | 2006 | 320 | 0.050 |
Why?
| | Longitudinal Studies | 1 | 2011 | 2844 | 0.050 |
Why?
| | HIV Infections | 1 | 2019 | 2836 | 0.050 |
Why?
| | Neoplasms | 1 | 2018 | 2671 | 0.050 |
Why?
| | Collagen | 1 | 2006 | 452 | 0.050 |
Why?
| | Nitrates | 2 | 2005 | 92 | 0.050 |
Why?
| | Monocytes | 1 | 2006 | 563 | 0.050 |
Why?
| | Fibroblasts | 1 | 2008 | 996 | 0.050 |
Why?
| | Lung Diseases | 2 | 2009 | 767 | 0.050 |
Why?
| | Databases, Factual | 2 | 2019 | 1357 | 0.050 |
Why?
| | Analgesia | 1 | 2024 | 94 | 0.050 |
Why?
| | Blood Pressure | 3 | 2016 | 1786 | 0.050 |
Why?
| | Patient Readmission | 2 | 2019 | 697 | 0.050 |
Why?
| | Antineoplastic Agents | 1 | 2014 | 2129 | 0.050 |
Why?
| | Complement Activation | 1 | 2006 | 415 | 0.050 |
Why?
| | Pulmonary Surfactant-Associated Proteins | 1 | 2002 | 10 | 0.050 |
Why?
| | Cathepsin G | 1 | 2002 | 6 | 0.050 |
Why?
| | Proteolipids | 1 | 2002 | 31 | 0.050 |
Why?
| | Cathepsins | 1 | 2002 | 24 | 0.050 |
Why?
| | Oxidative Stress | 1 | 2009 | 1317 | 0.050 |
Why?
| | Fever | 3 | 2001 | 306 | 0.050 |
Why?
| | Macromolecular Substances | 1 | 2002 | 229 | 0.050 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2006 | 445 | 0.050 |
Why?
| | Immunotherapy | 1 | 2006 | 641 | 0.050 |
Why?
| | Vasopressins | 1 | 2022 | 64 | 0.050 |
Why?
| | Heart Diseases | 1 | 2005 | 346 | 0.050 |
Why?
| | Jumonji Domain-Containing Histone Demethylases | 1 | 2002 | 62 | 0.050 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 1 | 2001 | 77 | 0.050 |
Why?
| | Colorado | 1 | 2011 | 4565 | 0.050 |
Why?
| | Vasoconstrictor Agents | 1 | 2022 | 139 | 0.040 |
Why?
| | Serine Endopeptidases | 1 | 2002 | 123 | 0.040 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 2003 | 220 | 0.040 |
Why?
| | Norepinephrine | 1 | 2022 | 204 | 0.040 |
Why?
| | Pulmonary Surfactants | 1 | 2002 | 106 | 0.040 |
Why?
| | Cell Line, Tumor | 1 | 2009 | 3412 | 0.040 |
Why?
| | Critical Care Outcomes | 1 | 2020 | 12 | 0.040 |
Why?
| | Status Asthmaticus | 1 | 2020 | 11 | 0.040 |
Why?
| | Recombinant Proteins | 1 | 2004 | 1353 | 0.040 |
Why?
| | Cell Differentiation | 1 | 2008 | 1991 | 0.040 |
Why?
| | Carbon Dioxide | 2 | 2001 | 267 | 0.040 |
Why?
| | Cell Communication | 1 | 2002 | 315 | 0.040 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 2 | 2001 | 350 | 0.040 |
Why?
| | Young Adult | 4 | 2019 | 13209 | 0.040 |
Why?
| | Epigenesis, Genetic | 1 | 2025 | 660 | 0.040 |
Why?
| | Vascular Resistance | 2 | 2016 | 375 | 0.040 |
Why?
| | Glycoproteins | 1 | 2002 | 342 | 0.040 |
Why?
| | Chronic Disease | 1 | 2006 | 1793 | 0.040 |
Why?
| | Sputum | 1 | 2002 | 311 | 0.040 |
Why?
| | Autoimmunity | 1 | 2006 | 908 | 0.040 |
Why?
| | NADPH Oxidase 2 | 2 | 2010 | 39 | 0.040 |
Why?
| | Cross-Over Studies | 2 | 1999 | 564 | 0.040 |
Why?
| | Dyspnea | 1 | 2001 | 254 | 0.040 |
Why?
| | NADPH Oxidases | 2 | 2010 | 113 | 0.040 |
Why?
| | Cyclic GMP | 1 | 1999 | 93 | 0.040 |
Why?
| | Macrophage Inflammatory Proteins | 1 | 1999 | 11 | 0.040 |
Why?
| | Case-Control Studies | 2 | 2017 | 3556 | 0.040 |
Why?
| | Mice, Inbred BALB C | 2 | 2013 | 1272 | 0.040 |
Why?
| | Endothelium, Vascular | 2 | 2003 | 927 | 0.040 |
Why?
| | Prevalence | 1 | 2025 | 2734 | 0.040 |
Why?
| | Infusions, Intravenous | 1 | 1999 | 413 | 0.040 |
Why?
| | Hospitals, Rural | 1 | 2018 | 39 | 0.040 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2004 | 1477 | 0.040 |
Why?
| | Hospital Charges | 1 | 2017 | 44 | 0.030 |
Why?
| | Comparative Effectiveness Research | 1 | 2018 | 152 | 0.030 |
Why?
| | Hospitals, Urban | 1 | 2018 | 134 | 0.030 |
Why?
| | Cellular Reprogramming | 1 | 2018 | 99 | 0.030 |
Why?
| | Time Factors | 2 | 2018 | 6828 | 0.030 |
Why?
| | Bayes Theorem | 1 | 2019 | 405 | 0.030 |
Why?
| | Muscular Diseases | 1 | 2017 | 114 | 0.030 |
Why?
| | Thrombocytopenia | 1 | 2018 | 200 | 0.030 |
Why?
| | Protein Binding | 1 | 2002 | 2224 | 0.030 |
Why?
| | Teichoic Acids | 1 | 2016 | 14 | 0.030 |
Why?
| | Surveys and Questionnaires | 1 | 2009 | 5778 | 0.030 |
Why?
| | Cytokines | 3 | 2013 | 2085 | 0.030 |
Why?
| | Biomarkers | 2 | 2019 | 4149 | 0.030 |
Why?
| | Receptors, Interleukin-1 | 1 | 1996 | 216 | 0.030 |
Why?
| | Acute Kidney Injury | 2 | 2014 | 815 | 0.030 |
Why?
| | Comorbidity | 1 | 2020 | 1622 | 0.030 |
Why?
| | Systole | 1 | 2016 | 189 | 0.030 |
Why?
| | Lung Diseases, Interstitial | 1 | 2002 | 638 | 0.030 |
Why?
| | Capillary Permeability | 1 | 2016 | 145 | 0.030 |
Why?
| | Risk | 1 | 2018 | 912 | 0.030 |
Why?
| | Receptors, Tumor Necrosis Factor, Type II | 2 | 2009 | 43 | 0.030 |
Why?
| | Toll-Like Receptor 2 | 1 | 2016 | 115 | 0.030 |
Why?
| | Cell Membrane | 2 | 2010 | 738 | 0.030 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2017 | 549 | 0.030 |
Why?
| | Transcription Factors | 1 | 2003 | 1719 | 0.030 |
Why?
| | Amino Acid Oxidoreductases | 1 | 1994 | 19 | 0.030 |
Why?
| | Dogs | 2 | 2006 | 413 | 0.030 |
Why?
| | Immunologic Factors | 1 | 1996 | 236 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2017 | 812 | 0.030 |
Why?
| | Ipilimumab | 1 | 2014 | 33 | 0.030 |
Why?
| | ROC Curve | 1 | 2016 | 554 | 0.030 |
Why?
| | Administration, Inhalation | 1 | 2016 | 688 | 0.030 |
Why?
| | Hemorrhage | 1 | 2018 | 722 | 0.030 |
Why?
| | Flow Cytometry | 2 | 2009 | 1178 | 0.030 |
Why?
| | Recombinant Fusion Proteins | 1 | 1996 | 665 | 0.030 |
Why?
| | Toll-Like Receptor 4 | 1 | 2016 | 273 | 0.030 |
Why?
| | Infliximab | 1 | 2014 | 111 | 0.030 |
Why?
| | Mice, 129 Strain | 1 | 2013 | 88 | 0.030 |
Why?
| | Blood Urea Nitrogen | 1 | 2013 | 54 | 0.030 |
Why?
| | Phylogeny | 1 | 2017 | 904 | 0.030 |
Why?
| | Diarrhea | 1 | 2014 | 184 | 0.020 |
Why?
| | Hypotension | 1 | 2014 | 122 | 0.020 |
Why?
| | Endothelial Cells | 2 | 2010 | 785 | 0.020 |
Why?
| | Logistic Models | 1 | 2017 | 2074 | 0.020 |
Why?
| | Cardiac Catheterization | 1 | 2016 | 530 | 0.020 |
Why?
| | Transfection | 2 | 2006 | 945 | 0.020 |
Why?
| | Vasoconstriction | 1 | 2013 | 202 | 0.020 |
Why?
| | Antioxidants | 1 | 2016 | 584 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 2 | 2010 | 2486 | 0.020 |
Why?
| | Healthcare Disparities | 1 | 2018 | 654 | 0.020 |
Why?
| | Trachea | 1 | 2013 | 237 | 0.020 |
Why?
| | Pulmonary Circulation | 1 | 2013 | 429 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 1999 | 3284 | 0.020 |
Why?
| | Creatinine | 1 | 2013 | 499 | 0.020 |
Why?
| | Ceramidases | 1 | 2010 | 4 | 0.020 |
Why?
| | Zymosan | 1 | 2010 | 65 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2013 | 1316 | 0.020 |
Why?
| | Nitric Oxide Synthase | 2 | 2005 | 240 | 0.020 |
Why?
| | Lung Compliance | 1 | 2009 | 49 | 0.020 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2009 | 87 | 0.020 |
Why?
| | RNA, Messenger | 2 | 2010 | 2833 | 0.020 |
Why?
| | Capillaries | 1 | 2009 | 108 | 0.020 |
Why?
| | Gene Deletion | 1 | 2010 | 391 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 976 | 0.020 |
Why?
| | Rats | 2 | 2010 | 5647 | 0.020 |
Why?
| | 3T3 Cells | 1 | 2008 | 163 | 0.020 |
Why?
| | Binding, Competitive | 1 | 2008 | 202 | 0.020 |
Why?
| | Leukocytes | 1 | 2009 | 311 | 0.020 |
Why?
| | Pulmonary Emphysema | 1 | 2010 | 288 | 0.020 |
Why?
| | Interleukin-10 | 1 | 2009 | 302 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 852 | 0.020 |
Why?
| | Melanoma | 1 | 2014 | 760 | 0.020 |
Why?
| | ATP Binding Cassette Transporter 1 | 1 | 2006 | 10 | 0.020 |
Why?
| | Receptors, LDL | 1 | 2006 | 47 | 0.020 |
Why?
| | Gene Targeting | 1 | 2006 | 81 | 0.020 |
Why?
| | Syk Kinase | 1 | 2006 | 21 | 0.020 |
Why?
| | Fetal Distress | 1 | 2006 | 13 | 0.020 |
Why?
| | Random Allocation | 1 | 2006 | 353 | 0.020 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2006 | 108 | 0.010 |
Why?
| | Immunity | 1 | 2006 | 143 | 0.010 |
Why?
| | Hyperoxia | 1 | 2006 | 90 | 0.010 |
Why?
| | Nitrites | 1 | 2005 | 84 | 0.010 |
Why?
| | Respiratory Distress Syndrome, Newborn | 1 | 2006 | 106 | 0.010 |
Why?
| | RNA Interference | 1 | 2006 | 469 | 0.010 |
Why?
| | Tumor Suppressor Proteins | 1 | 2006 | 327 | 0.010 |
Why?
| | Caenorhabditis elegans Proteins | 1 | 2006 | 199 | 0.010 |
Why?
| | Child | 2 | 2021 | 21935 | 0.010 |
Why?
| | Drug Therapy, Combination | 1 | 2006 | 1066 | 0.010 |
Why?
| | Survival Analysis | 1 | 2006 | 1325 | 0.010 |
Why?
| | Genes, Dominant | 1 | 2003 | 96 | 0.010 |
Why?
| | Proportional Hazards Models | 1 | 2006 | 1266 | 0.010 |
Why?
| | Homeostasis | 1 | 2006 | 621 | 0.010 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2006 | 434 | 0.010 |
Why?
| | Chimera | 1 | 2002 | 58 | 0.010 |
Why?
| | Oxidation-Reduction | 1 | 2006 | 1060 | 0.010 |
Why?
| | Hypoxia | 1 | 2009 | 1112 | 0.010 |
Why?
| | Neutrophil Infiltration | 1 | 2002 | 107 | 0.010 |
Why?
| | Neovascularization, Physiologic | 1 | 2003 | 179 | 0.010 |
Why?
| | Double-Blind Method | 1 | 2006 | 1993 | 0.010 |
Why?
| | Stroke Volume | 1 | 2005 | 612 | 0.010 |
Why?
| | Respiratory Muscles | 1 | 2001 | 33 | 0.010 |
Why?
| | Interleukin-1 | 2 | 1996 | 965 | 0.010 |
Why?
| | Blood Gas Analysis | 1 | 2001 | 74 | 0.010 |
Why?
| | Cell Count | 1 | 2002 | 324 | 0.010 |
Why?
| | Enzyme Inhibitors | 1 | 2005 | 840 | 0.010 |
Why?
| | Cell Division | 1 | 2003 | 794 | 0.010 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2002 | 165 | 0.010 |
Why?
| | Chemokines | 1 | 2002 | 228 | 0.010 |
Why?
| | Stress, Mechanical | 1 | 2003 | 485 | 0.010 |
Why?
| | Bone Marrow Transplantation | 1 | 2002 | 286 | 0.010 |
Why?
| | Bleomycin | 1 | 2002 | 248 | 0.010 |
Why?
| | Hyaluronic Acid | 1 | 2002 | 225 | 0.010 |
Why?
| | Proteins | 1 | 2006 | 1009 | 0.010 |
Why?
| | Chemokine CCL3 | 1 | 1999 | 16 | 0.010 |
Why?
| | Chemokine CCL4 | 1 | 1999 | 23 | 0.010 |
Why?
| | Cyclooxygenase Inhibitors | 1 | 1999 | 79 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2003 | 1738 | 0.010 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 1999 | 164 | 0.010 |
Why?
| | Shivering | 1 | 1996 | 5 | 0.010 |
Why?
| | Acute-Phase Reaction | 1 | 1996 | 41 | 0.010 |
Why?
| | Lactoferrin | 1 | 1996 | 31 | 0.010 |
Why?
| | Toxemia | 1 | 1996 | 5 | 0.010 |
Why?
| | Blood Cell Count | 1 | 1996 | 55 | 0.010 |
Why?
| | Sialoglycoproteins | 1 | 1996 | 159 | 0.010 |
Why?
| | Solubility | 1 | 1996 | 245 | 0.010 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 1996 | 253 | 0.010 |
Why?
| | Kinetics | 1 | 1999 | 1670 | 0.010 |
Why?
| | Calmodulin | 1 | 1994 | 76 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2006 | 6079 | 0.010 |
Why?
| | Cytosol | 1 | 1994 | 226 | 0.010 |
Why?
| | Phenotype | 1 | 2002 | 3196 | 0.010 |
Why?
| | Electrocardiography | 1 | 1996 | 629 | 0.010 |
Why?
| | Peptide Fragments | 1 | 1996 | 706 | 0.010 |
Why?
| | Lung Neoplasms | 1 | 2006 | 2526 | 0.010 |
Why?
| | Cattle | 1 | 1994 | 984 | 0.010 |
Why?
| | Hemodynamics | 1 | 1996 | 1113 | 0.010 |
Why?
| | Interferon-gamma | 1 | 1994 | 789 | 0.010 |
Why?
| | Sulfonamides | 1 | 1994 | 513 | 0.010 |
Why?
| | Prospective Studies | 1 | 1996 | 7604 | 0.000 |
Why?
|
|
Vandivier's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|